

# Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis

Tanawin Nopsopon<sup>1</sup>, Jathurong Kittrakulrat<sup>2</sup>, Kullaya Takkavatakarn<sup>3</sup>, Thanee Eiamsitrakoon<sup>4</sup>, Talerngsak Kanjanabuch<sup>3</sup>, Krit Pongpirul<sup>1,5,6\*</sup>

<sup>1</sup>Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

<sup>2</sup>Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

<sup>3</sup>Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

<sup>4</sup>Division of Nephrology, Department of Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand

<sup>5</sup>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

<sup>6</sup>Bumrungrad International Hospital, Bangkok, Thailand

\* Corresponding author

E-mail: [doctorkrit@gmail.com](mailto:doctorkrit@gmail.com)

Words: 3,252 words, Abstract 250 words

## Abstract

### Introduction

The novel coronavirus (COVID-19), caused by SARS-CoV-2, showed various prevalence and case-fatality rates (CFR) among patients with different pre-existing chronic conditions. End-stage renal disease (ESRD) patients with renal replacement therapy (RRT) might have a higher prevalence and CFR due to reduced immune function from uremia and kidney tropism of SARS-CoV-2, but there was no systematic study on the infection and mortality of the SARS-CoV-2 infection in ESRD patients who are on RRT.

### Methods

We searched five electronic databases and performed a systematic review and meta-analysis up to June 30, 2020, to evaluate the prevalence and case fatality rate (CFR) of the COVID-19 infection among ESRD patients with RRT. The global COVID-19 data were retrieved from the international database on June 30, 2020, for estimating the prevalence and CFR of the general population as referencing points.

### Results

Of 3,272 potential studies, 34 were eligible studies consisted of 1,944 COVID-19 confirmed cases in 21,873 ESRD patients with RRT from 12 countries in four WHO regions. The overall pooled prevalence in ESRD patients with RRT was 3.10% [95% confidence interval (CI) 1.25–5.72] which was higher than referencing 0.14% global average prevalence. The overall estimated CFR of COVID-19 in ESRD patients with RRT was 18.06% (95%CI 14.09–22.32) which was higher than the global average at 4.98%.

### Conclusions

This meta-analysis suggested high COVID-19 prevalence and CFR in ESRD patients with RRT. ESRD patients with RRT should have their specific protocol of COVID-19 prevention and treatment to mitigate excess cases and deaths.

## Author summary

Chronic kidney disease (CKD) was associated with increasing severity and mortality of COVID-19. End-stage renal disease (ESRD) patients were at the terminal stage of CKD and had reduced immune function due to uremia. Additionally, ESRD patients with kidney transplantation had a diminished immune system from immunosuppressive agents. Kidneys might be the secondary target of SARS-CoV-2 after the respiratory tract regardless of the previous history of kidney disease, preferably the glomerulus, which was associated with the richness of some specific protein-coding genes in the kidney. The overall pooled prevalence in ESRD patients with renal replacement therapy was approximately 22 times of the referencing global average prevalence. The overall estimated case fatality rate of COVID-19 in ESRD patients with renal replacement therapy was approximately 3.6 times the global average. ESRD patients with renal replacement therapy had high COVID-19 prevalence and case fatality rate. We suggested that ESRD patients with renal replacement therapy should have their specific protocol of COVID-19 prevention and treatment to mitigate excess cases and deaths.

## Introduction

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was first reported in December 2019 as a newly discovered causative pathogen of patients with pneumonia of unknown cause in Wuhan, China[1]. Since its debut, the novel coronavirus (COVID-19) has drastically spread throughout the globe, and the World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020[2]. The global COVID-19 data from the international database at mid-year of 2020 reported 217 countries affected by the novel coronavirus with more than ten million people infected with SARS-CoV-2; approximately half a million patients died from the novel disease[3].

Pre-existing comorbidities have been reported to be associated with the severity of hospitalized COVID-19 patients[4]. Chronic kidney disease was found to be associated with the severity and mortality of COVID-19[5]. Specifically, patients with chronic kidney disease had a three-fold risk of developing severe COVID-19[6]. About one-third of end-stage renal disease (ESRD) patients with dialysis who were hospitalized with COVID-19 were died[7]. The high mortality rate might be associated with the diminished immune system from uremia in ESRD

patients[8]. Moreover, kidney transplanted patients had reduced immune response from immunosuppressive agents[9].

Kidneys might be the secondary target of SARS-CoV-2 after the respiratory tract regardless of the previous history of kidney disease as indicated from the second-highest SARS-CoV-2 viral load found in the kidneys of the autopsy in COVID-19 death cases, preferably the glomerulus, which was associated with the richness of protein-coding genes including angiotensin-converting enzyme 2 (*ACE2*), transmembrane serine protease 2 (*TMPRSS2*), and cathepsin L (*CTSL*) in the kidney[10]. There was a high number of hospitalized COVID-19 patients who subsequently developed acute kidney injury (AKI) during the disease course(5), especially patients with kidney transplantation[11]. Several systematic reviews reported the association of AKI in COVID-19 patients with more severity and poor prognosis of COVID-19[12-14]. Despite the evidence on the association of COVID-19 and subsequent kidney damage, whether patients with severe chronic kidney disease, especially those with renal replacement therapy (RRT), had higher COVID-19 infection and death than individuals with normal kidney functions has still been inconclusive. In this review, we performed a meta-analysis to evaluate the prevalence and case fatality rate of COVID-19 in patients with ESRD with RRT.

## Methods

This study was conducted following the recommendations of the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) statement[15]. We prospectively registered the systematic review with PROSPERO International Prospective Register of Ongoing Systematic Reviews (Registration number: CRD42020199752).

### Search strategy

PubMed, Embase, Scopus, Web of Science, and Cochrane Central Register of Clinical Trials were used to systematically search for articles published in the English language up to June 30, 2020. The terms “Coronavirus”, “COVID-19” and “SARS-CoV-2” were used in combination with “Chronic kidney disease”, “End-stage renal disease”, “Renal replacement therapy”, “Dialysis”, “Hemodialysis”, “Peritoneal Dialysis” and “Kidney Transplantation” as the keywords for literature search along with their synonyms. The search strategy is presented in

detail in Supplementary S2Table. Additionally, the reference lists of included articles were searched, as well as related citations from other journals via Google Scholar.

## Study selection

We worked with an information specialist to design an appropriate search strategy to identify original peer-reviewed articles of randomized controlled trials and observational studies evaluating the prevalence or mortality outcomes, or both of COVID-19 in ESRD patients with RRT (KT, HD, or PD) without restriction on age, gender, ethnicity, duration of chronic kidney disease, or previous treatment. Additional outcomes were the need for mechanical ventilation (MV) and intensive care unit (ICU) admission. Article screening was done by two independent reviewers for eligible studies. Discrepancies between the two reviewers were resolved by consensus.

## Data extraction

Data extraction was done by two independent reviewers for published summary estimate data. Discrepancies between the two reviewers were resolved by consensus. We extracted the following data: (1) study characteristics (authors, year of publication, study type, journal name, contact information, country, and funding), (2) patients characteristics (sample size, age, gender, type of renal replacement therapy, COVID-19 diagnostic criteria, COVID-19 treatment), (3) outcomes (complete list of the names of all measured outcomes, unit of measurement, follow-up time point, missing data) as well as any other relevant information. All relevant text, tables, and figures were examined for data extraction. We contacted the authors of the study with incompletely reported data. If the study authors did not respond within 14 days, we conducted analyses using the available data.

The global COVID-19 data were retrieved from the international database(3) on June 30, 2020, for estimating the prevalence and CFR of the general population as referencing points. The global COVID-19 data in general population comprised of 7,525,172,273 population, 10,566,205 COVID-19 confirmed cases, and 526,163 COVID-19 death cases in 217 countries. The global average prevalence of COVID-19 in the general population was 0.14%, and the global average CFR of COVID-19 in the general population was 4.98%.

## Quality assessment

The authors worked independently to assess the risk of bias in the included studies using the risk of bias tool by Hoy et al. for studies with COVID-19 prevalence outcomes[16]. We assessed the representativeness of the sample, sampling frame, sampling techniques, response rate, data collection method, case definition, measurement tools, study period, and data calculation. We assigned each domain as a low risk of bias and a high risk of bias while the overall risk of bias was reported as a low risk of bias, a moderate risk of bias, and a high risk of bias. The included studies with COVID-19 mortality data were assessed for risk of bias with the non-summative four-domain system (consecutive cases, multicenter, more than 80% follow-up, multivariable analysis) developed by Wylde et al[17]. We assigned each domain as adequate, inadequate, and not reported. This system was preferred because the domain was applicable with both controlled observational studies and case series. We contacted the authors if there was insufficient information to assess. If the study authors did not respond within 14 days, we conducted the risk of bias assessment using available data. We resolve the disagreement through discussion. We presented our risk of bias assessment in Supplementary S1Table.

## Statistical analysis

The primary outcomes were COVID-19 prevalence and COVID-19 deaths. The prevalence outcomes were measured with the percentage of COVID-19 confirmed cases and total ESRD with RRT patients with an associated 95% confidence interval (CI). The death outcomes were measured as CFR with the percentage of COVID-19 deaths and total COVID-19 confirmed cases in ESRD with RRT patients with an associated 95% CI. The additional outcomes were the need for mechanical ventilation and ICU admission among hospitalized COVID-19 confirmed cases in ESRD with RRT patients with an associated 95% CI. The results of the studies were included in the meta-analysis and presented in a forest plot, which also showed statistical powers, confidence intervals, and heterogeneity. This meta-analysis was performed to find pooled estimated value with a 95% confidence interval and did not have a comparator group, thus no null hypothesis was tested. Instead, we compared the estimated values of primary outcomes with global averages.

We assessed clinical and methodological heterogeneity by examining participant characteristics, follow-up period, outcomes, and study designs. We then assessed statistical heterogeneity using the  $I^2$  statistic. We regarded level of heterogeneity for  $I^2$  statistic as defined in chapter 9 of the Cochrane Handbook for Systematic Reviews of Interventions: 0–40% might not be important; 30–60% may represent moderate heterogeneity; 50–90% may

represent substantial heterogeneity; 75–100% considerable heterogeneity. The Freeman-Tukey double arcsine transformation was used to ensure admissible confidence intervals. The random-effects meta-analysis by DerSimonian and Laird method was used as clinical, methodological, and statistical heterogeneity encountered. The exact method was used for confidence interval computation. Prespecified subgroup analyses, including country income level, WHO country region, and RRT modality, were performed. We assessed publication bias in two ways. First, we computed each study effect size against standard error and plotted it as a funnel plot to assess asymmetry visually. Second, we used Egger’s test to statistically test for asymmetry. The significant asymmetry indicated the possibility of publication bias or heterogeneity. The meta-analysis was performed using STATA 16.1 (StataCorp, TX, USA).

## Results

### Characteristics of the studies

The database search identified 3,272 potential records. After duplicate removal, 1,885 titles passed the initial screening, and 212 theme-related abstracts were selected for further full-text articles assessment for eligibility (Fig 1). A total of 178 articles were excluded as the following: 44 letters to the editor, 36 case reports, 26 wrong populations, 19 wrong outcomes, 16 editorials, 12 review articles, nine duplicates, nine recommendation, three commentaries, two non-English, and two protocols. Only 34 studies were eligible for data synthesis and meta-analysis.

### Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart of study selection and database search.

All 34 included studies were published in 2020, of which 15 studies reported prevalence outcomes[18-32] and 31 studies reported death outcomes[7, 18, 21-24, 26-50]. There were 17 cohort studies[7, 19, 20, 23-25, 27, 31, 33, 35, 40, 42, 44-46, 49, 50], 12 case series[21, 30, 34, 36-39, 41, 43, 47, 48], and five cross-sectional studies[22, 26, 28, 29, 32]. The number of samples per study ranged from 3 to 7,154 with a total of 1,944 COVID-19 confirmed cases in 21,873 ESRD patients with RRT from 12 countries in four WHO regions which nine countries were high-

180 income countries and three were upper-middle-income countries according to the World Bank classification[51].  
 181 The mean age varied from 45.0 to 73.6 years. Female patients in each study were ranged from 0 to 57%. There were  
 182 20 studies on ESRD patients with kidney transplantation (KT) only[21, 23, 24, 26, 28, 30, 34-39, 41, 43, 45-50], ten  
 183 studies with hemodialysis (HD) only[18-20, 22, 25, 27, 29, 32, 33, 40], four studies with more than one RRT  
 184 modalities[7, 31, 42, 44], and no studies with peritoneal dialysis (PD) only (Table1).



185 **Table 1. Characteristics of included studies.**

Author	Country	Income Level	WHO Regions	Study Design	Mean Age, yr (SD)	Female %	Total Sample	COVID-19 Cases	RRT Modality	Diagnostic Criteria	COVID-19 Treatment	Admission Cases	IV Steroid Cases
Wang <sup>15</sup>	China	UMICs	Western Pacific	Case Series	Range 47-67	40.0*	201	5	HD	PCR	Umifenovir, Ribavirin	5	NR
Wu <sup>30</sup>	China	UMICs	Western Pacific	Cohort	Med 62 (IQR 54-71)	36.7	49	49	HD	PCR	NR	49	NR
Xiong <sup>16</sup>	China	UMICs	Western Pacific	Cohort	63.3 (13.2)	NR	7154	154	HD	PCR	NR	NR	NR
Xu <sup>17</sup>	China	UMICs	Western Pacific	Cohort	NR	43.3	1542	5	HD	PCR	NR	NR	NR
Zhang <sup>18</sup>	China	UMICs	Western Pacific	Case Series	45 (11)	20.0*	743	5	KT	NAT	Oseltamivir, Umifenovir	5	1
Zhu <sup>31</sup>	China	UMICs	Western Pacific	Case Series	Range 24-65	20.0	10	10	KT	PCR, IMG	Umifenovir, Oseltamivir, Ribavirin, Ganciclovir	10	5
Bösch <sup>32</sup>	Germany	HICs	European	Cohort	Med 61	33.3	3	3	KT	PCR	None	3	0
Abrishami <sup>33</sup>	Iran	UMICs	Eastern Mediterranean	Case Series	47.66 (1.35)	25.0	12	12	KT	PCR, IMG, SYM, Lab	HCQ, LPV/r	12	12
Alberici a <sup>19</sup>	Italy	HICs	European	Cross-sect	Med 72 (IQR 62-79)	34.0*	643	94	HD	PCR	HCQ, LPV/r, DRV/r	57	18
Alberici b <sup>34</sup>	Italy	HICs	European	Case Series	59	20	20	20	KT	PCR	HCQ, LPV/r, DRV/r	20	11
Maritati <sup>20</sup>	Italy	HICs	European	Cohort	Med 72	40*	585	5	KT	PCR	HCQ, LPV/r	5	NR
Mella <sup>35</sup>	Italy	HICs	European	Case Series	55.5 (8.4)	0	6	6	KT	PCR, IMG	HCQ, DRV/r	6	NR
Hoek <sup>21</sup>	Netherlands	HICs	European	Cohort	Range 21-81	31.3*	2150	16	KT	PCR, SYM	NR	NR	NR
Kolonko <sup>36</sup>	Poland	HICs	European	Case Series	Med 42	0	3	3	KT	PCR	None	3	NR
Cho <sup>22</sup>	South Korea	HICs	Western Pacific	Cohort	Med 57	36.4*	1175	11	HD	PCR	NR	11	NR
Jung <sup>37</sup>	South Korea	HICs	Western Pacific	Cohort	63.5 (14.5)	57.1	14	14	HD	PCR	HCQ, LPV/r	14	3
Crespo <sup>23</sup>	Spain	HICs	European	Cross-sect	73.6 (4.7)	20*	803	20	KT	PCR	HCQ, LPV/r, DRV/r	9	NR
Fernández-Ruiz <sup>38</sup>	Spain	HICs	European	Case Series	Range 39-80	12.5	8	8	KT	PCR	HCQ, LPV/r	8	NR
Goicoechea <sup>24</sup>	Spain	HICs	European	Cohort	71 (12)	36.1*	282	36	HD	PCR	HCQ, LPV/r	36	NR
Melgosa <sup>39</sup>	Spain	HICs	European	Cohort	NR	NR	6	6	KT, HD	PCR	HCQ, LPV/r	NR	NR
Rodríguez-	Spain	HICs	European	Case Series	Med 66 (IQR 59-72)	41.4	29	29	KT	PCR	HCQ	29	18

Cubillo <sup>40</sup>													
Sánchez-Álvarez <sup>41</sup>	Spain	HICs	European	Cohort	68.3 (14.7)	NR	868	868	KT, HD, PD	PCR	HCQ, LPV/r	NR	NR
Tschopp <sup>42</sup>	Switzerland	HICs	European	Cohort	Range 35-87	38.5	13	13	KT	PCR	HCQ, LPV/r	12	NR
Akdur <sup>43</sup>	Turkey	UMICs	European	Cross-sect	NR	31.8	509	1	KT	PCR	HCQ	0	0
Arsilan <sup>44</sup>	Turkey	UMICs	European	Cross-sect	64	42.7	602	7	HD	PCR, IMG	NR	NR	NR
Banerjee <sup>45</sup>	UK	HICs	European	Case Series	Med 54	42.9*	2082	7	KT	PCR	None	5	0
Corbett <sup>46</sup>	UK	HICs	European	Cohort	Med 66 (IQR 55-75)	41.8	1530	300	HD, PD	PCR	NR	NR	NR
Roper <sup>47</sup>	UK	HICs	European	Cross-sect	Median 63.2	40.4	670	76	HD	PCR	NR	NR	NR
Chen <sup>48</sup>	USA	HICs	The Americas	Cohort	56 (12)	46.7	30	30	KT	PCR	HCQ	30	NR
Columbia U <sup>49</sup>	USA	HICs	The Americas	Case Series	Med 51 (IQR 28-72)	33.3	15	15	KT	NR	HCQ	15	NR
Fung <sup>50</sup>	USA	HICs	The Americas	Case Series	Range 44-77	28.6	7	7	KT	PCR	HCQ, LPV/r	5	NR
Mehta <sup>51</sup>	USA	HICs	The Americas	Cohort	Med 59 (IQR 53-64)	34.3	35	35	KT	PCR	HCQ	34	NR
Valeri <sup>52</sup>	USA	HICs	The Americas	Cohort	Med 63 (IQR 56-78)	44.1	59	59	HD, PD	PCR	HCQ	59	NR
Yi <sup>53</sup>	USA	HICs	The Americas	Cohort	NR	NR	15	15	KT	PCR	HCQ, Ribavirin	11	1

186 \*Female % of COVID-19 confirmed cases in end-stage renal disease patients with RRT.

187 Cross-sect, cross-sectional. DRV/r, Darunavir/Ritonavir. HCQ, Hydroxychloroquine. HD, hemodialysis. HICs, high-income countries. IMG, imaging. IQR, interquartile range. IV, intravenous. KT,

188 kidney transplantation. LPV/r, Lopinavir/Ritonavir. Med, median. NAT, nucleic acid test. NR, not reported. PCR, polymerase chain reaction. PD, peritoneal dialysis. RRT, renal replacement therapy.

189 SD, standard deviation. SYM, symptoms. UMICs, upper-middle-income countries. WHO, World Health Organization

In 27 studies, the diagnostic criteria to confirm COVID-19 case were polymerase chain reaction (PCR) assay only. While five studies used a combination of PCR and additional criteria to diagnose COVID-19: imaging (three studies), suggestive symptoms (one study), and a combination of imaging, suggestive symptoms, and laboratory tests (one study). One study did not explicitly state the diagnostic criteria. For COVID-19 treatment, Hydroxychloroquine was the most common treatment used in 20 studies, followed by Lopinavir/Ritonavir used in 12 studies. Some studies used other medications including Darunavir/Ritonavir, Oseltamivir, Umifenovir, Ribavirin, and Ganciclovir. Three studies reported no specific COVID-19 treatment, and eight studies did not report information on COVID-19 treatment.

## **Risk of bias**

For the risk of bias assessment of 15 included studies with prevalence outcomes, 12 studies had a mild overall risk of bias, and three studies had a moderate overall risk of bias. The domain with a high risk of bias was the representativeness of the sample followed by sampling frame, sampling techniques, and response rate. For 31 included studies that reported mortality outcomes, there were a high number of inadequate in multicenter studies and multivariable analysis domains while the consecutive case and more than 80% follow-up were adequate in most studies (Supplementary S1Table). While the funnel plot showed some visual asymmetry, Egger's test for asymmetry highlighted no evidence of publication bias on overall estimated prevalence ( $p=0.418$ ). The funnel plot and Egger's test highlighted no evidence of publication bias on the overall estimated case fatality rate ( $p=0.569$ ) (Supplementary S1 Fig).

## **Prevalence of COVID-19**

Fifteen studies that reported the prevalence of COVID-19 in ESRD patients with RRT were included in the meta-analysis of 20,671 ESRD with RRT patients from seven countries[18-32]. The overall pooled prevalence was 3.10% [95% confidence interval (CI) 1.25–5.72] which was higher than referencing 0.14% global average prevalence (Fig 2). The highest COVID-19 prevalence in ESRD patients was reported in the United Kingdom [19.61% (95% CI 17.65–21.69)][31] whereas the lowest COVID-19 prevalence was reported in Turkey [0.20% (95% CI 0.00–1.09%)] [28].

**Fig 2. Forest plot for the prevalence of COVID-19 in ESRD patients with RRT.** The figure summarizes the number of COVID-19 confirmed cases in end-stage renal disease (ESRD) patients with renal replacement therapy (RRT) and the total number of ESRD patients with RRT in 15 eligible studies. The forest plot represents the estimated prevalence of COVID-19 in ESRD patients with RRT for each study (black boxes), with 95% confidence intervals (95% CI; horizontal black lines). The estimated pooled prevalence (red diamond) was 3.10% (95% CI 1.25–5.72). The global average prevalence (vertical red line) was 0.14%. The meta-analysis used a random-effects model with the exact method for confidence interval estimation. ES, effect size.  $I^2$ , test for heterogeneity.

Six studies were from two upper-middle-income countries[18-21, 28, 29] and nine studies were from five high-income countries[22-27, 30-32]. The pooled COVID-19 prevalence in upper-middle-income countries was 0.95% (95% CI 0.28–1.97) which was lower than the pooled prevalence in high-income countries at 5.11% (95% CI 1.37–10.97) (Fig 3). With WHO Region categorization, there were ten studies in the European region[22-24, 26-32], and five studies in Western Pacific region[18-21, 25]. COVID-19 estimated prevalence in the European region was 4.41% (95% CI 1.11–9.69) which was higher than the Western Pacific region at 1.10% (95% CI 0.36–2.19) (Fig4).

**Fig 3. Forest plot for the prevalence of COVID-19 in ESRD patients with RRT by country income level.** The figure summarizes the number of COVID-19 confirmed cases in ESRD patients with RRT and the total number of ESRD patients with RRT in 15 eligible studies with subgroup analysis by the World Bank country income level. The forest plot represents the estimated prevalence of COVID-19 in ESRD patients with RRT for each study (black boxes), with 95% confidence intervals (95% CI; horizontal black lines). The estimated pooled prevalence for each subgroup was presented with a red diamond. The overall estimated pooled prevalence (last red diamond) was 3.10% (95% CI 1.25–5.72). The global average prevalence (vertical red line) was 0.14%. The meta-analysis used a random-effects model with the exact method for confidence interval estimation. ES, effect size.  $I^2$ , test for heterogeneity.

**Fig 4. Forest plot for the prevalence of COVID-19 in ESRD patients with RRT by WHO country region.** The figure summarizes the number of COVID-19 confirmed cases in ESRD patients with RRT and the total number of ESRD patients with RRT in 15 eligible studies with subgroup analysis by WHO country regions. The forest plot represents the estimated prevalence of COVID-19 in ESRD patients with RRT for each study (black boxes), with 95% confidence intervals (95% CI; horizontal black lines). The estimated pooled prevalence for each subgroup was presented with a red diamond. The overall estimated pooled prevalence (last red diamond) was 3.10% (95% CI 1.25–5.72). The global average prevalence (vertical red line) was 0.14%. The meta-analysis used a random-effects model with the exact method for confidence interval estimation. ES, effect size.  $I^2$ , test for heterogeneity.

Eight studies focused on COVID-19 prevalence in ESRD patients with HD only with a pooled COVID-19 prevalence of 4.26% (95% CI 1.68–7.91)[18-20, 22, 25, 27, 29, 32]. Six studies had data on prevalence of COVID-19 in KT patients only with a pooled prevalence of 0.76% (95% CI 0.33–1.35)[21, 23, 24, 26, 28, 30]. Only one study had mixed data of COVID-19 prevalence in ESRD patients with HD or PD with a prevalence of 19.61% (95% CI 17.65–21.69) (Fig5)[31]. There was no study with ESRD patients with peritoneal dialysis only.

**Fig 5. Forest plot for the prevalence of COVID-19 in ESRD patients with RRT by RRT modality.** The figure summarizes the number of COVID-19 confirmed cases in ESRD patients with RRT and the total number of ESRD patients with RRT in 15 eligible studies with subgroup analysis by types of RRT modality. The forest plot represents the estimated prevalence of COVID-19 in ESRD patients with RRT for each study (black boxes), with 95% confidence intervals (95% CI; horizontal black lines). The estimated pooled prevalence for each subgroup was presented with a red diamond. The overall estimated pooled prevalence (last red diamond) was 3.10% (95% CI 1.25–5.72). The global average prevalence (vertical red line) was 0.14%. The meta-analysis used a random-effects model with the exact method for confidence interval estimation. ES, effect size.  $I^2$ , test for heterogeneity.

## Case Fatality Rate of COVID-19

Thirty-one studies with death outcomes among 1,774 COVID-19 confirmed cases in ESRD with RRT from 12 countries[7, 18, 21-24, 26-50]. The overall estimated CFR of COVID-19 in ESRD patients with RRT was 18.06% (95%CI 14.09–22.32) which was higher than the global average at 4.98% (Fig 6).

**Fig 6. Forest plot for the case fatality rate of COVID-19 in ESRD patients with RRT.** The figure summarizes the number of COVID-19 deaths in ESRD patients with RRT and the number of COVID-19 confirmed cases in ESRD patients with RRT in 31 eligible studies. The forest plot represents the estimated case fatality rate of COVID-19 in ESRD patients with RRT for each study (black boxes), with 95% confidence intervals (95% CI; horizontal black lines). The estimated pooled case fatality rate (red diamond) was 18.06% (95%CI 14.09–22.32). The global case fatality rate (vertical red line) was 4.98%. The meta-analysis used a random-effects model with the exact method for confidence interval estimation. ES, effect size.  $I^2$ , test for heterogeneity.

Of 31 studies, seven studies were from three upper-middle-income countries[18, 21, 28, 29, 33, 34, 36] and 24 studies were from nine high income countries[7, 22-24, 26, 27, 30-32, 35, 37-50]. The estimated CFR of COVID-19 in ESRD patients with RRT in upper-middle-income countries was 8.95% (95% CI 0.00–30.00), while the estimated CFR in high-income countries was 19.65% (95%CI 15.94–23.60) (Fig 7). Nineteen studies were from the European region with an estimated CFR of 18.77% (95%CI 14.16–23.74)[22-24, 26-32, 35, 37-39, 41-45], six studies were from the Americas region with an estimated CFR of 17.01% (95%CI 9.36–26.08)[7, 46-50], five studies were from Western Pacific region with an estimated CFR of 9.51% (95%CI 2.97–18.20)[18, 21, 33, 34, 40], and one study was from Eastern Mediterranean region with CFR of 66.67% (95%CI 34.89–90.08) (Fig 8)(36).

**Fig 7. Forest plot for the case fatality rate of COVID-19 in ESRD patients with RRT by country income level.** The figure summarizes the number of COVID-19 deaths in ESRD patients with RRT and the number of COVID-19 confirmed cases in ESRD patients with RRT in 31 eligible studies with subgroup analysis by the World Bank country income level. The forest plot represents the estimated case fatality rate of COVID-19 in ESRD patients with

RRT for each study (black boxes), with 95% confidence intervals (95% CI; horizontal black lines). The estimated pooled case fatality rate for each subgroup was presented with a red diamond. The overall estimated pooled case fatality rate (last red diamond) was 18.06% (95%CI 14.09–22.32). The global case fatality rate (vertical red line) was 4.98%. The meta-analysis used a random-effects model with the exact method for confidence interval estimation. ES, effect size.  $I^2$ , test for heterogeneity.

**Fig 8. Forest plot for the case fatality rate of COVID-19 in ESRD patients with RRT by WHO country region.**

The figure summarizes the number of COVID-19 deaths in ESRD patients with RRT and the number of COVID-19 confirmed cases in ESRD patients with RRT in 31 eligible studies with subgroup analysis by WHO country regions. The forest plot represents the estimated case fatality rate of COVID-19 in ESRD patients with RRT for each study (black boxes), with 95% confidence intervals (95% CI; horizontal black lines). The estimated pooled case fatality rate for each subgroup was presented with a red diamond. The overall estimated pooled case fatality rate (last red diamond) was 18.06% (95%CI 14.09–22.32). The global case fatality rate (vertical red line) was 4.98%. The meta-analysis used a random-effects model with the exact method for confidence interval estimation. ES, effect size.  $I^2$ , test for heterogeneity.

Seven studies focused on COVID-19 CFR in ESRD patients with HD only with an estimated CFR of 14.87% (95%CI 6.87–24.76)[18, 22, 27, 29, 32, 33, 40]. Twenty studies on ESRD patients with KT only reported an estimated CFR of 19.28% (95%CI 12.20–27.20)[21, 23, 24, 26, 28, 30, 34-39, 41, 43, 45-50]. Only four studies had CFR data for mixed RRT modalities (Fig 9)[7, 31, 42, 44].

**Fig 9. Forest plot for the case fatality rate of COVID-19 in ESRD patients with RRT by RRT modality.**

The figure summarizes the number of COVID-19 deaths in ESRD patients with RRT and the number of COVID-19 confirmed cases in ESRD patients with RRT in 31 eligible studies with subgroup analysis by types of RRT modality. The forest plot represents the estimated case fatality rate of COVID-19 in ESRD patients with RRT for each study (black boxes), with 95% confidence intervals (95% CI; horizontal black lines). The estimated pooled case fatality rate for each subgroup was presented with a red diamond. The overall estimated pooled case fatality

rate (last red diamond) was 18.06% (95%CI 14.09–22.32). The global case fatality rate (vertical red line) was 4.98%. The meta-analysis used a random-effects model with the exact method for confidence interval estimation. ES, effect size.  $I^2$ , test for heterogeneity.

## Need for Mechanical Ventilation and Intensive Care Unit (ICU) Admission Rate

Twenty-one studies that reported mechanical ventilation rate of hospitalized COVID-19 cases were included in the meta-analysis of 377 hospitalized COVID-19 cases from nine countries[7, 21, 23, 26, 27, 30, 33-38, 40, 41, 43, 45-50]. The overall mechanical ventilation rate of COVID-19 in hospitalized ESRD patients with RRT was 38.75% (95%CI 28.38-49.56).

Fifteen studies from nine countries, which consisted of 223 hospitalized COVID-19 cases in ESRD patients with RRT, reported ICU admission rate[21, 23, 26, 27, 30, 33, 35-37, 40, 41, 43, 45, 48, 50]. The overall ICU admission rate of COVID-19 in hospitalized ESRD patients with RRT was 28.31% (95% CI13.84–44.97). Forest plots with subgroup analysis were provided in SupplementaryS2 and S3 Figs.

## Discussion

To our knowledge, this is the first systematic review and meta-analysis of studies focusing on the prevalence and CFR of the novel coronavirus in ESRD patients with various renal replacement therapy modalities. The pooled data showed that the prevalence and CFR of COVID-19 in ESRD patients with RRT were significantly higher than the global average in all populations[3]. The need for mechanical ventilation and ICU admission rate in hospitalized ESRD patients with RRT was also high. The outcomes were varied among country income level, WHO region, and type of RRT modality.

The overall pooled prevalence of COVID-19 in ESRD patients with RRT was higher than the global average prevalence (3.1% vs. 0.1%)[3]. Moreover, the overall pooled prevalence of COVID-19 in ESRD patients with RRT was higher than that of autoimmune disease patients (3.10% vs. 1.1%)[52] but was lower than that of colorectal cancer patients (3.1% vs. 45.1%)[53]. The increased prevalence in ESRD patients might relate to decreased immunity from uremia[8].



While no evidence of publication bias, there was substantial heterogeneity between studies on prevalence outcomes which might associate with country income level and RRT modality. Significant heterogeneity between upper-middle-income and high-income countries was suggested from the lower estimated pooled prevalence of upper-middle-income countries than high-income countries (0.95% vs. 5.11%). This might be partially explained by the fact that China, which had a relatively lower overall national COVID-19 prevalence than the high-income countries[3], was regarded as an upper-middle-income country. There was also a significant heterogeneity across RRT modalities which the HD patients had a considerably higher prevalence than the KT patients (4.26% vs. 0.76%). The result was unexpected because ESRD patients with KT were supposed to have lower immune function than ESRD patients with HD due to the use of the immunosuppressive drug[9]. Some ESRD with HD patients might need to visit a hospital for in-center hemodialysis during COVID-19 epidemics and pandemics which might increase the risk of SARS-CoV-2 exposure.

The overall CFR of COVID-19 in ESRD patients with RRT was higher than the global average (18.06% vs. 4.98%)[3]. Additionally, the overall estimated CFR of COVID-19 in ESRD patients with RRT was higher than the general population (18.06% vs 0.68 to 5.00%)[54-56], hypertensive (18.06% vs. 6.43%)[57], and autoimmune disease patients (18.06% vs 6.60%)[52]; but was lower than diabetes mellitus (18.06% vs. 19.25%)[58] and cancer patients (18.06% vs. 20.83 to 23.4%)[59, 60]. The diminished immune function might play a crucial role in the increased CFR among ESRD patients with RRT[8].

Despite no evidence of publication bias, there was considerable heterogeneity between studies on CFR across WHO regions from 9.51% in Western Pacific to 17.01% in the Americas and 18.77% in the European regions. The variation in CFR might associate with the relatively low national COVID-19 prevalence in China of the Western Pacific region compared to other included countries[3].

Several limitations of this systematic review and meta-analysis should be noted. First, the included studies had high heterogeneities for both prevalence and CFR outcomes. The subgroup analysis could not fully explore all sources of heterogeneity, given the limited availability of the information presented in the included studies. Second, there was no included study focused on ESRD patients with PD only. Thus, the prevalence and CFR of COVID-19 in PD patients might not be available. Third, we did not explore deeper into specific details of each RRT modality

such as type of HD, type of KT, and duration of RRT. Lastly, we included only English language articles that might miss some pieces of evidence in other languages.

In conclusion, our systematic review and meta-analysis provided the first evidence on the pooled prevalence and CFR of COVID-19 in ESRD patients with RRT which were higher than the global average. Increased prevalence and deaths might relate to reduced immune function in ESRD patients. ESRD patients with RRT should have their specific protocol of COVID-19 prevention and treatment to mitigate excess cases and deaths.

## Acknowledgments

The authors thank the investigators of all primary studies that were included in this meta-analysis.

## Author Contributions

**Conceptualization:** Talerngsak Kanjanabuch, Krit Pongpirul.

**Data curation:** Tanawin Nopsopon, Jathurong Kittrakulrat, Kullaya Takkavatakarn, Thanee Eiamsitrakoon.

**Formal analysis:** Tanawin Nopsopon.

**Investigation:** Tanawin Nopsopon, Jathurong Kittrakulrat, Krit Pongpirul.

**Methodology:** Tanawin Nopsopon, Talerngsak Kanjanabuch, Krit Pongpirul.

**Project administration:** Krit Pongpirul.

**Software:** Tanawin Nopsopon, Krit Pongpirul.

**Supervision:** Talerngsak Kanjanabuch, Krit Pongpirul.

**Validation:** Tanawin Nopsopon, Jathurong Kittrakulrat, Krit Pongpirul.

**Visualization:** Tanawin Nopsopon.

**Writing – original draft:** Tanawin Nopsopon, Krit Pongpirul.

**Writing – review & editing:** Tanawin Nopsopon, Jathurong Kittrakulrat, Kullaya Takkavatakarn, Thanee Eiamsitrakoon, Talerngsak Kanjanabuch, Krit Pongpirul.

**Data Availability Statement:** All relevant data are within the paper and its Supporting information files.

**Funding:** The author(s) received no specific funding for this work.

**Competing interests:** The authors have declared that no competing interests exist.

## References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33.
2. World Health Organization. Coronavirus disease 2019 (COVID-19). Situation Report 51.
3. Worldometers.info. COVID-19 Coronavirus Pandemic: Reported Cases and Deaths by Country, Territory, or Conveyance.
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *Jama*. 2020;323(11):1061-9.
5. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int*. 2020;97(5):829-38.
6. Henry B, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. *Int Urol Nephrol*. 2020;52(6):1193-4.
7. Valeri A, Robbins-Juarez S, Stevens J, Ahn W, Rao M, Radhakrishnan J, et al. Presentation and Outcomes of Patients with ESKD and COVID-19. *J Am Soc Nephrol*. 2020;31(7):1409-15.
8. Betjes M. Immune cell dysfunction and inflammation in end-stage renal disease. *Nat Rev Nephrol*. 2013;9(5):255-65.
9. Zhu L, Xu X, Ma K, Yang J, Guan H, Chen S, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. *Am J Transplant*. 2020;20(7):1859-63.
10. Puelles V, Lütgehetmann M, Lindenmeyer M, Sperhake J, Wong M, Allweiss L, et al. Multiorgan and Renal Tropism of SARS-CoV-2. *N Engl J Med*. 2020;383(6):590-2.
11. Yang X, Tian S, Guo H. Acute kidney injury and renal replacement therapy in COVID-19 patients: A systematic review and meta-analysis. *Int Immunopharmacol*. 2020:107159.
12. Fu EL, Janse R, de Jong Y, van der Endt V, Milders J, van der Willik E, et al. Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis. *Clin Kidney J*. 2020;13(4):550-63.
13. Yang X, Jin Y, Li R, Zhang Z, Sun R, Chen D. Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis. *Crit Care*. 2020;24(1):356.
14. Ali H, Daoud A, Mohamed M, Salim S, Yessayan L, Baharani J, et al. Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. *Ren Fail*. 2020;42(1):393-7.
15. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
16. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol*. 2012;65(9):934-9.
17. Wylde V, Beswick A, Dennis J, Gooberman-Hill R. Post-operative patient-related risk factors for chronic pain after total knee replacement: a systematic review. *BMJ Open*. 2017;7(11):e018105.
18. Wang R, Liao C, He H, Hu C, Wei Z, Hong Z, et al. COVID-19 in Hemodialysis Patients: A Report of 5 Cases. *Am J Kidney Dis*. 2020;76(1):141-3.
19. Xiong F, Tang H, Liu L, Tu C, Tian J, Lei C, et al. Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan, China. *J Am Soc Nephrol*. 2020;31(7):1387-97.
20. Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. *Nat Med*. 2020;26(8):1193-5.
21. Zhang H, Chen Y, Yuan Q, Xia Q, Zeng X, Peng J, et al. Identification of Kidney Transplant Recipients with Coronavirus Disease 2019. *Eur Urol*. 2020;77(6):742-7.

22. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. *Kidney Int.* 2020;98(1):20-6.
23. Maritati F, Cerutti E, Zuccatosta L, Fiorentini A, Finale C, Ficosecco M, et al. SARS-CoV-2 infection in kidney transplant recipients: Experience of the Italian Marche region. *Transpl Infect Dis.* 2020;22(5):e13377.
24. Hoek R, Manintveld O, Betjes M, Hellemons M, Seghers L, Van Kampen J, et al. COVID-19 in solid organ transplant recipients: a single-center experience. *Transpl Int.* 2020;33(9):1099-105.
25. Cho J, Kang S, Park H, Kim D, Lee S, Do J, et al. Hemodialysis with Cohort Isolation to Prevent Secondary Transmission during a COVID-19 Outbreak in Korea. *J Am Soc Nephrol.* 2020;31(7):1398-408.
26. Crespo M, Pérez-Sáez M, Redondo-Pachón D, Llinàs-Mallol L, Montero M, Villar-García J, et al. COVID-19 in elderly kidney transplant recipients. *Am J Transplant.* 2020;20(10):2883-9.
27. Goicoechea M, Sánchez Cámara L, Macías N, Muñoz de Morales A, Rojas Á G, Bascuñana A, et al. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain. *Kidney Int.* 2020;98(1):27-34.
28. Akdur A, Karakaya E, Ayvazoglu Soy E, Alshalabi O, Kirnap M, Arslan H, et al. Coronavirus Disease (COVID-19) in Kidney and Liver Transplant Patients: A Single-Center Experience. *Exp Clin Transplant.* 2020;18(3):270-4.
29. Arslan H, Musabak U, Ayvazoglu Soy E, Kurt Azap O, Sayin B, Akcay S, et al. Incidence and Immunologic Analysis of Coronavirus Disease (COVID-19) in Hemodialysis Patients: A Single-Center Experience. *Exp Clin Transplant.* 2020;18(3):275-83.
30. Banerjee D, Popoola J, Shah S, Ster I, Quan V, Phanish M. COVID-19 infection in kidney transplant recipients. *Kidney Int.* 2020;97(6):1076-82.
31. Corbett R, Blakey S, Nitsch D, Loucaidou M, McLean A, Duncan N, et al. Epidemiology of COVID-19 in an Urban Dialysis Center. *J Am Soc Nephrol.* 2020;31(8):1815-23.
32. Roper T, Kumar N, Lewis-Morris T, Moxham V, Kassimatis T, Game D, et al. Delivering Dialysis During the COVID-19 Outbreak: Strategies and Outcomes. *Kidney Int Rep.* 2020;5(7):1090-4.
33. Wu J, Li J, Zhu G, Zhang Y, Bi Z, Yu Y, et al. Clinical Features of Maintenance Hemodialysis Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *Clin J Am Soc Nephrol.* 2020;15(8):1139-45.
34. Zhu L, Gong N, Liu B, Lu X, Chen D, Chen S, et al. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China. *Eur Urol.* 2020;77(6):748-54.
35. Bösch F, Börner N, Kemmner S, Lampert C, Jacob S, Koliogiannis D, et al. Attenuated early inflammatory response in solid organ recipients with COVID-19. *Clin Transplant.* 2020;34(10):e14027.
36. Abrishami A, Samavat S, Behnam B, Arab-Ahmadi M, Nafar M, Sanei Taheri M. Clinical Course, Imaging Features, and Outcomes of COVID-19 in Kidney Transplant Recipients. *Eur Urol.* 2020;78(2):281-6.
37. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. *Kidney Int.* 2020;97(6):1083-8.
38. Mella A, Mingozzi S, Gallo E, Lavacca A, Rossetti M, Clari R, et al. Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab. *Transpl Infect Dis.* 2020:e13348.
39. Kolonko A, Dudzicz S, Wiecek A, Król R. COVID-19 infection in solid organ transplant recipients: A single-center experience with patients immediately after transplantation. *Transpl Infect Dis.* 2020:e13381.

40. Jung H, Lim J, Kang S, Kim S, Lee Y, Lee J, et al. Outcomes of COVID-19 among Patients on In-Center Hemodialysis: An Experience from the Epicenter in South Korea. *J Clin Med*. 2020;9(6).
41. Fernández-Ruiz M, Andrés A, Loinaz C, Delgado J, López-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. *Am J Transplant*. 2020;20(7):1849-58.
42. Melgosa M, Madrid A, Álvarez O, Lumbreras J, Nieto F, Parada E, et al. SARS-CoV-2 infection in Spanish children with chronic kidney pathologies. *Pediatr Nephrol*. 2020;35(8):1521-4.
43. Rodríguez-Cubillo B, de la Higuera M, Lucena R, Franci E, Hurtado M, Romero N, et al. Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? *Am J Transplant*. 2020;20(11):3173-81.
44. Sánchez-Álvarez J, Pérez Fontán M, Jiménez Martín C, Blasco Pelicano M, Cabezas Reina C, Sevillano Prieto Á M, et al. SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). *Nefrologia*. 2020;40(3):272-8.
45. Tschopp J, L'Huillier A, Mombelli M, Mueller N, Khanna N, Garzoni C, et al. First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. *Am J Transplant*. 2020;20(10):2876-82.
46. Chen T, Farghaly S, Cham S, Tatem L, Sin J, Rauda R, et al. COVID-19 pneumonia in kidney transplant recipients: Focus on immunosuppression management. *Transpl Infect Dis*. 2020;22(5):e13378.
47. Columbia University Kidney Transplant Program. Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York. *J Am Soc Nephrol*. 2020;31(6):1150-6.
48. Fung M, Chiu C, DeVoe C, Doernberg S, Schwartz B, Langelier C, et al. Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States. *Am J Transplant*. 2020;20(11):3225-33.
49. Mehta S, Leonard J, Labella P, Cartiera K, Soomro I, Neumann H, et al. Outpatient management of kidney transplant recipients with suspected COVID-19-Single-center experience during the New York City surge. *Transpl Infect Dis*. 2020:e13383.
50. Yi S, Rogers A, Saharia A, Aoun M, Faour R, Abdelrahim M, et al. Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center. *Transplantation*. 2020;104(11):2208-14.
51. The World Bank. Country Classification. World Bank Country and Lending Group.
52. Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. *Ann Rheum Dis*. 2020.
53. Antikchi M, Neamatzadeh H, Ghelmani Y, Jafari-Nedooshan J, Dastgheib S, Kargar S, et al. The Risk and Prevalence of COVID-19 Infection in Colorectal Cancer Patients: a Systematic Review and Meta-analysis. *J Gastrointest Cancer*. 2020:1-7.
54. Li L, Huang T, Wang Y, Wang Z, Liang Y, Huang T, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol*. 2020;92(6):577-83.
55. Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. *Int J Infect Dis*. 2020;101:138-48.
56. Khalili M, Karamouzian M, Nasiri N, Javadi S, Mirzazadeh A, Sharifi H. Epidemiological characteristics of COVID-19: a systematic review and meta-analysis. *Epidemiol Infect*. 2020;148:e130.
57. Zhang J, Wu J, Sun X, Xue H, Shao J, Cai W, et al. Association of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. *Epidemiol Infect*. 2020;148:e106.
58. Wu J, Zhang J, Sun X, Wang L, Xu Y, Zhang Y, et al. Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 (COVID-19) infection. *Diabetes Obes Metab*. 2020;22(10):1907-14.

59. Salunke A, Nandy K, Pathak S, Shah J, Kamani M, Kottakota V, et al. Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14(5):1431-7.
60. Zhang H, Han H, He T, Labbe K, Hernandez A, Chen H, et al. Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2020.

## Supporting information

### S1 Checklist. PRISMA checklist

(DOCX)

### S1 Fig. Funnel plot: estimated prevalence and case fatality rate with standard error of each included study in meta-analysis

(PDF)

### S2 Fig. Forest plots with subgroup analysis: mechanical ventilation rate

(PDF)

### S3 Fig. Forest plots with subgroup analysis: ICU admission rate

(PDF)

### S1 Table. Risk of bias assessment

(DOCX)


### S2 Table. Full search strategy

(DOCX)






## PRISMA 2009 Flow Diagram



# Prevalence of COVID-19 in ESRD Patients with Renal Replacement Therapy


medRxiv preprint doi: <https://doi.org/10.1101/2021.01.25.21250454>; this version posted January 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.






# Prevalence of COVID-19 in ESRD Patients with Renal Replacement Therapy by Country Income Level

medRxiv preprint doi: <https://doi.org/10.1101/2021.01.25.21260434>; this version posted January 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



# Prevalence of COVID-19 in ESRD Patients with Renal Replacement Therapy by WHO Country Region


medRxiv preprint doi: <https://doi.org/10.1101/2021.01.25.21260434>; this version posted January 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.





# Prevalence of COVID-19 in ESRD Patients with Renal Replacement Therapy by RRT Modality


medRxiv preprint doi: <https://doi.org/10.1101/2021.01.25.21250454>; this version posted January 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.





# Case Fatality Rate of COVID-19 in ESRD Patients with Renal Replacement Therapy


medRxiv preprint doi: <https://doi.org/10.1101/2021.01.25.21250454>; this version posted January 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.





# Case Fatality Rate of COVID-19 in ESRD Patients with Renal Replacement Therapy by Country Income Level


medRxiv preprint doi: <https://doi.org/10.1101/2021.01.25.21250454>; this version posted January 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.





# Case Fatality Rate of COVID-19 in ESRD Patients with Renal Replacement Therapy by WHO Country Region

medRxiv preprint doi: <https://doi.org/10.1101/2021.01.25.21250454>; this version posted January 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.





# Case Fatality Rate of COVID-19 in ESRD Patients with Renal Replacement Therapy by RRT Modality

medRxiv preprint doi: <https://doi.org/10.1101/2021.01.25.21250454>; this version posted January 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

